20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
In the latest quarter, 10 analysts provided ratings for Colgate-Palmolive (NYSE:CL), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 1 | 4 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 4 | 1 | 3 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Colgate-Palmolive, revealing an average target of $93.4, a high estimate of $100.00, and a low estimate of $84.00. This upward trend is evident, with the current average reflecting a 4.81% increase from the previous average price target of $89.11.
Understanding Analyst Ratings: A Comprehensive Breakdown
The standing of Colgate-Palmolive among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Lauren Lieberman | Barclays | Raises | Equal-Weight | $85.00 | $84.00 |
| Chris Carey | Wells Fargo | Raises | Equal-Weight | $92.00 | $90.00 |
| Mark Astrachan | Stifel | Raises | Buy | $95.00 | $94.00 |
| Bryan Spillane | B of A Securities | Raises | Buy | $100.00 | $90.00 |
| Nik Modi | RBC Capital | Raises | Sector Perform | $95.00 | $88.00 |
| Filippo Falorni | Citigroup | Raises | Buy | $100.00 | $95.00 |
| Lauren Lieberman | Barclays | Raises | Equal-Weight | $84.00 | $82.00 |
| Mark Astrachan | Stifel | Raises | Buy | $94.00 | $89.00 |
| Robert Ottenstein | Evercore ISI Group | Raises | Outperform | $96.00 | $90.00 |
| Jason English | Goldman Sachs | Announces | Buy | $93.00 | - |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Colgate-Palmolive. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Colgate-Palmolive compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Colgate-Palmolive's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Colgate-Palmolive's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Colgate-Palmolive analyst ratings.
Discovering Colgate-Palmolive: A Closer Look
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oralcare line, the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International accounts for about 70% of its total sales base, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
A Deep Dive into Colgate-Palmolive's Financials
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Colgate-Palmolive's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 6.18%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Staples sector.
Net Margin: Colgate-Palmolive's net margin is impressive, surpassing industry averages. With a net margin of 13.48%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Colgate-Palmolive's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 162.81%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Colgate-Palmolive's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.14%, the company showcases efficient use of assets and strong financial health.
Debt Management: Colgate-Palmolive's debt-to-equity ratio surpasses industry norms, standing at 37.78. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
What Are Analyst Ratings?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!